University Medical Center Groningen (UMCG)
Welcome,         Profile    Billing    Logout  
 48 Trials 
41 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vries, Elisabeth GE de
CBT307-1, NCT05836623: A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions

Active, not recruiting
1
5
Europe
Radiolabelled CB307, 89Zr-CB307, CB307
Crescendo Biologics Ltd., University Medical Center Groningen
Advanced and/or Metastatic Solid Tumours
01/24
10/24
POTENTIA, NCT04839991: Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.

Recruiting
1
70
Europe, US
CB307
Crescendo Biologics Ltd.
Advanced and/or Metastatic Solid Tumours
07/24
09/24
NCT03850028 / 2017-003511-20: Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Withdrawn
N/A
20
Europe
89Zr-atezolizumab PET scans
University Medical Center Groningen, Amsterdam UMC, location VUmc, Stichting Hemato-Oncologie voor Volwassenen Nederland, Hoffmann-La Roche
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
05/22
05/22
Soo, Ross
STEREO, NCT04908956 / 2020-004114-35: Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC

Terminated
2
6
Europe, RoW
Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT)
ETOP IBCSG Partners Foundation, AstraZeneca
NSCLC Stage IV, EGFR Gene Mutation
10/23
02/24
AMAZE-lung, NCT05601973 / 2021-002337-42: Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

Recruiting
2
60
Europe
Amivantamab, Lazertinib, Zirabev
ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals
Non Small Cell Lung Cancer
03/26
09/26
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT04909073: Observational Study of Afatinib 30 mg Daily

Recruiting
N/A
69
RoW
Afatinib, Giotrif
National University Hospital, Singapore, Boehringer Ingelheim
Non-Small Cell Lung Cancer, Epidermal Growth Factor Receptor Mutation
05/25
12/25
Slebos, Dirk-Jan
CONVERT, NCT04559464: Fissure Closure With the AeriSeal System for ing Collateral Ventilation Status

Completed
N/A
102
Europe, RoW
AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System
Pulmonx Corporation
Emphysema, COPD, Severe Emphysema
10/23
10/24
NCT06035120: An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients with Severe Emphysema

Recruiting
N/A
200
Europe, US, RoW
AeriSeal System
Pulmonx Corporation
Emphysema, Pulmonary, Emphysema or COPD
06/27
03/28
IAB-1, NCT05087641: A Multicenter, Prospective Trial of the IAB in Adults Suffering From COPD/Emphysema

Active, not recruiting
N/A
20
Europe, RoW
IAB System
Pulmair Medical, Inc.
Emphysema, Pulmonary Disease, Chronic Obstructive
04/24
01/27
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
10/24
09/28
BREATHE-2, NCT05949645: Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema

Active, not recruiting
N/A
30
Europe
Apreo Implant Group
Apreo Health, Inc.
Emphysema or COPD
10/24
06/26
Huls, Gerwin G
AML21, NCT02172872 / 2014-001486-27: "InDACtion" vs "3+7" Induction in AML

Active, not recruiting
3
606
Europe, RoW
standard combination chemotherapy, "3+7" induction chemotherapy, Intensive combined chemotherapy, decitabine, Dacogen
European Organisation for Research and Treatment of Cancer - EORTC, Janssen Pharmaceuticals, Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia (AML)
03/22
12/23
NCT05949125: Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123

Recruiting
1
37
Europe
Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment
AvenCell Europe GmbH, Allucent (NL) BV
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
12/25
06/26
Jänisch, Thomas
ORCHESTRA-4, NCT05222139: Monitoring COVID-19 Vaccination Response in Fragile Populations

Active, not recruiting
N/A
8894
Europe, RoW
COVID-19 vaccination
University of Bologna, Universita di Verona, Hospital Universitario Virgen Macarena, Azienda Ospedaliera di Padova, Azienda Ospedaliero-Universitaria di Parma, Azienda Ulss 2 Marca Trevigiana, University College Dublin, Luxembourg Institute of Health, ICONA Foundation, University Medical Center Groningen, University of Buenos Aires, PENTA Foundation, Universiteit Antwerpen, Institut National de la Santé Et de la Recherche Médicale, France, Helmholtz Zentrum München, CINECA consorzio universitario italiano, Charite University, Berlin, Germany, Centre de Recherche Médicale de Lambaréné
SARS CoV 2 Infection, Vaccination; Infection, Breakthrough Infection
07/23
11/24
Dam, Gooitzen van
ACT-BOOSTER, NCT05124483: Anti-COVID19 VaccinaTion AKS-452 BOOSTER ( Study)

Recruiting
2
600
Europe
AKS-452X
University Medical Center Groningen, TRACER Europe BV, PRA Health Sciences
COVID-19
07/22
02/23
VARTUTRACE, NCT06645808: PET-imaging of Two Vartumabs in Patients with Solid Tumors

Recruiting
1
32
Europe
89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
Var2 Pharmaceuticals, TRACER Europe BV
Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma, Chondrosarcoma, Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Pancreas Carcinoma, Bladder Carcinoma, Glioblastoma
01/26
01/26
Nagengast, W B
STRATIFY, NCT03938701: Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

Not yet recruiting
1
30
Europe
Adalimumab-800CW, Humira, Fluorescence Imaging
University Medical Center Groningen, AbbVie
IBD, Rheumatoid Arthritis
06/24
12/24
Hartman, Jorine
CONVERT, NCT04559464: Fissure Closure With the AeriSeal System for ing Collateral Ventilation Status

Completed
N/A
102
Europe, RoW
AeriSeal, Zephyr Valves, Bronchoscopic Lung Volume Reduction (BLVR), Zephyr System
Pulmonx Corporation
Emphysema, COPD, Severe Emphysema
10/23
10/24
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis

Active, not recruiting
N/A
270
Europe, US
RheOx Bronchial Rheoplasty, Sham Procedure
Gala Therapeutics, Inc.
Chronic Bronchitis
05/24
10/25
AIRFLOW-3, NCT03639051: Evaluation of the Safety and Efficacy of TLD in Patients with COPD

Active, not recruiting
N/A
464
Europe, US
Targeted Lung Denervation (TLD), TLD, TLD Therapy, Optimal Medical Care
Nuvaira, Inc.
COPD
10/24
09/28
Ares, Luis Paz
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Active, not recruiting
3
758
Europe, Canada, Japan, US, RoW
Cobolimab, Dostarlimab, Docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
04/25
10/25
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
Calles, Antonio
LUPER, NCT04358237 / 2019-002261-35: Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.

Active, not recruiting
1/2
28
Europe
Lurbinectedin, PM01183, Zepsyre, Pembrolizumab, Keytruda
Antonio Calles Blanco, MedSIR, PharmaMar, Merck Sharp & Dohme LLC
Small Cell Lung Carcinoma
09/23
03/25
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

Recruiting
1/2
153
Europe, US
avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063
Verastem, Inc., Amgen
Non Small Cell Lung Cancer, KRAS Activating Mutation
09/25
04/27
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
Muijs, Kristel
PROTECT, NCT05055648: PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy

Recruiting
3
396
Europe
Photon Radiotherapy, Proton Radiotherapy, Proton Therapy
University of Aarhus, University of Leeds, KU Leuven, University College, London, Aarhus University Hospital, Technische Universität Dresden, Academisch Ziekenhuis Groningen, CNAO National Center of Oncological Hadrontherapy, Agenzia Nazionale per i Servizi Sanitari Regionali, Centre Antoine Lacassagne, Centre Leon Berard, Institut Curie, Maastro Clinic, The Netherlands, University College London Hospitals, The Christie NHS Foundation Trust, Paul Scherrer Institut, Center for Proton Therapy, HollandPTC, IBA worldwide, Varian- A Siemens Healthineer Company
Esophageal Cancer, Radiotherapy, Side Effect, Proton Therapy
12/27
12/32
Eerkens, Anneke
PAM-II, NCT06180733 / 2022-003922-27: Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer

Recruiting
2
12
Europe
Pembrolizumab Injection [Keytruda]
University Medical Center Groningen, Merck Sharp & Dohme LLC
Endometrial Cancer
12/27
01/28
Verhaar, Anne-Fleur
CHASE, NCT06204237: Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography)

Recruiting
1
10
Europe
[89Zr]Zr-DFO-APAC, PET/CT scan
Aplagon Oy, TRACER Europe BV
Peripheral Arterial Occlusive Disease, Critical Limb Ischemia
06/25
06/25
VARTUTRACE, NCT06645808: PET-imaging of Two Vartumabs in Patients with Solid Tumors

Recruiting
1
32
Europe
89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
Var2 Pharmaceuticals, TRACER Europe BV
Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma, Chondrosarcoma, Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Pancreas Carcinoma, Bladder Carcinoma, Glioblastoma
01/26
01/26
Tan, Aaron
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT05910827: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

Recruiting
1/2
98
RoW
HMBD-001, Docetaxel, Cetuximab
Hummingbird Bioscience, Merck KGaA, Darmstadt, Germany
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma
03/26
03/26
Links, Mirthe
No trials found

Download Options